Page last updated: 2024-11-12

cinobufagin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cinobufagin: isolated from Chinese medicinal preparation ch'an su; derived from toad venom [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11969542
CHEMBL ID250785
CHEBI ID80805
SCHEMBL ID642990
MeSH IDM0043067

Synonyms (37)

Synonym
cinobufagine
470-37-1
nsc-90325
5.beta.-bufa-20, 14,15.beta.-epoxy-3.beta.,16.beta.-dihydroxy-, 16-acetate
cino-bufagin
bufa-20, 16-(acetyloxy)-14,15-epoxy-3-hydroxy-, (3.beta.,5.beta.,15.beta.,16.beta.)-
NSC90325 ,
cinobufagin
5beta-bufa-20,22-dienolide, 14,15beta-epoxy-3beta,16beta-dihydroxy-, 16-acetate
nsc 90325
bufa-20,22-dienolide, 16-(acetyloxy)-14,15-epoxy-3-hydroxy-, (3-beta,5-beta,15-beta,16-beta)-
chebi:80805 ,
CHEMBL250785
C16931
S3224
t9psn4r8ir ,
unii-t9psn4r8ir
cinobufagin [who-dd]
bufa-20,22-dienolide, 16-(acetyloxy)-14,15-epoxy-3-hydroxy-, (3- .beta.,5-.beta.,15-.beta.,16-.beta.)-
CCG-208337
SCHEMBL642990
CS-3697
AC-34292
Q-100496
HY-N0421
mfcd00056825
SR-05000002305-2
sr-05000002305
Q5121070
36121-84-3
14,15beta-epoxy-3beta,16beta-dihydroxy-5beta,20(22)-bufadienolide 16-acetate
C3460
AMY40639
[(1r,2s,4r,5r,6r,7r,10s,11s,14s,16r)-14-hydroxy-7,11-dimethyl-6-(6-oxopyran-3-yl)-3-oxapentacyclo[8.8.0.02,4.02,7.011,16]octadecan-5-yl] acetate
DTXSID701026953
cinobufagin (cinobufagine)
AKOS040753754

Research Excerpts

Overview

Cinobufagin is a cardiotoxic steroid secreted by the Asiatic toad Bufo gargarizans. It is an active component in the anti-tumor Chinese medicine called "Chan Su"

ExcerptReferenceRelevance
"Cinobufagin is a natural product isolated from the traditional chinese medicine Chansu."( Cinobufagin restrains the growth and triggers DNA damage of human hepatocellular carcinoma cells via proteasome-dependent degradation of thymidylate synthase.
Chen, Q; Li, H; Sun, Y; Tao, Y; Wang, A; Wu, Q; Yang, A; Yang, J; Zhang, J, 2022
)
2.89
"Cinobufagin (CBF) is a bufadienolide, which is a major active ingredient of toad venom. "( Pharmacological Effects of Cinobufagin.
Jian, B; Kuang, H; Zhang, H, 2023
)
2.65
"Cinobufagin (CBF) is an active ingredient isolated from Venenum Bufonis extracted and dried from the secretory glands of Bufo gargarizans Cantor. "( Anti-proliferative and pro-apoptotic effects of cinobufagin on human breast cancer MCF-7 cells and its molecular mechanism.
Chen, C; Chen, Y; Cheng, J; Ji, Z; Wei, C; Yang, X; Yang, Z; Zhu, L, 2018
)
2.18
"Cinobufagin is an active component in the anti-tumor Chinese medicine called "Chan Su", and we previously revealed that cinobufagin induced apoptosis and reduced the viability of osteosarcoma cells; however, the underlying mechanism remains to be elucidated."( Cinobufagin Induces Apoptosis in Osteosarcoma Cells Via the Mitochondria-Mediated Apoptotic Pathway.
Cheng, AY; Dai, G; Guo, W; Yang, J; Zheng, D, 2018
)
2.64
"Cinobufagin is a cardiotoxic bufanolide steroid secreted by the Asiatic toad Bufo gargarizans. "( Inhibition of autophagy enhances cinobufagin‑induced apoptosis in gastric cancer.
Guo, H; Li, X; Lu, B; Tian, Q; Wang, Y; Wu, M; Xiong, X; Zhang, H; Zhang, Q; Zhou, T, 2019
)
2.24
"Cinobufagin is a promising natural anti-angiogenetic drug that has clinical translation potential and practical application value."( Cinobufagin suppresses colorectal cancer angiogenesis by disrupting the endothelial mammalian target of rapamycin/hypoxia-inducible factor 1α axis.
Chen, C; Dai, Y; Han, Q; Huang, C; Jing, L; Li, X; Liu, Y; Ma, Y; Sun, X; Wang, J; Xu, Y; Yao, X; Zhao, L, 2019
)
2.68
"Cinobufagin (CBG) is a cardiotoxic bufanolide steroid secreted by the skin and parotid venom glands of the Asiatic toad Bufo bufo gargarizans (called Chan-Su). "( Cinobufagin exerts anti-proliferative and pro-apoptotic effects through the modulation ROS-mediated MAPKs signaling pathway.
Ahn, KS; Baek, SH; Chung, WS; Jang, HJ; Kim, C; Kim, SH; Lee, J; Lee, JH; Lee, SG; Nam, D, 2015
)
3.3
"Cinobufagin (1) is a major bufadienolide in ChanSu (a traditional Chinese medicine) with a wide range of pharmacological activities. "( Identification of cinobufagin metabolites in the bile of rats.
Liu, KX; Ma, XC; Ning, J; Tian, G; Tian, Y; Wang, CY; Wu, TH; Zhang, BJ, 2010
)
2.14

Effects

ExcerptReferenceRelevance
"The cinobufagin (CB) has a broad spectrum of cytotoxicity to inhibit cell proliferation of various human cancer cell lines, but the molecular mechanisms still remain elusive. "( Cinobufagin inhibits tumor growth by inducing intrinsic apoptosis through AKT signaling pathway in human nonsmall cell lung cancer cells.
Cui, R; Hua, P; Jin, C; Li, J; Liu, R; Nguyen, LL; Song, G; Sun, M; Wang, B; Wang, C; Wang, L; Zhang, G; Zhang, X; Zhang, Y, 2016
)
2.44
"Cinobufagin (CBG) has been shown to have antinociceptive properties. "( Alpha-7 Nicotinic Receptor-Targeted Cinobufagin Induces Antinociception and Inhibits NF-κB Signaling Pathway in DRG Neurons.
Feng, Q; Ni, H; Shen, H; Xu, L; Yao, M; Zhang, X; Zheng, Y, 2019
)
2.23

Treatment

ExcerptReferenceRelevance
"Cinobufagin treatment decreased the expression of Notch-1, and Hes-1, Hes-5 and Hey-1 gene expression in OS cell lines."( Cinobufagin induces apoptosis of osteosarcoma cells through inactivation of Notch signaling.
Cao, Y; Dai, G; Gao, T; Guo, W; Yu, L; Zhang, S; Zhang, Z, 2017
)
2.62

Toxicity

Cinobufagin is a monomer isolated from Venenum Bufonis (VB) It has shown pharmacological effects in various models, but its toxic effect is elusive in brain cell models.

ExcerptReferenceRelevance
"In this study, we aimed to compare the analgesic and toxic effects of Venenum Bufonis (VB) with those of cinobufagin (CBG), a monomer isolated from VB, to provide the experimental basis for further research and development of VB."( Analgesic and toxic effects of venenum bufonis and its constituent compound cinobufagin: A comparative study.
Feng, Q; Ni, H; Shen, H; Wang, S; Xu, L; Yao, M; Zhang, X,
)
0.57
" Although cinobufagin was shown to display pharmacological effects in various models, the toxic effect of cinobufagin is elusive in brain cell models."( Investigation of cytotoxic effect of the bufanolide steroid compound cinobufagin and its related underlying mechanism in brain cell models.
Hsu, SS; Liang, WZ; Lin, YS, 2021
)
1.26

Compound-Compound Interactions

GEMOX combined with huachansu (cinobufagin) injection is well tolerated, effective, thus improving the QOL of patients with advanced GBC.

ExcerptReferenceRelevance
" These results suggest that bufalin in combination with VP16, all-trans retinoic acid, 1 alpha,25-dihydroxyvitamin D3, rTNF-alpha, or gamma-interferon may be very useful in the differentiation of human leukemia."( Induction by bufalin of differentiation of human leukemia cells HL60, U937, and ML1 toward macrophage/monocyte-like cells and its potent synergistic effect on the differentiation of human leukemia cells in combination with other inducers.
Kuroiwa, Y; Nakaya, K; Yoshida, T; Zhang, L, 1992
)
0.28
"To evaluate the efficacy and safety of gemcitabine-oxaliplatin (GEMOX) combined with huachansu (cinobufagin) injection treatment in patients with locally advanced or metastatic gallbladder carcinoma (GBC), and to assess the quality of life (QOL) of such patients."( Efficacy and safety of gemcitabine-oxaliplatin combined with huachansu in patients with advanced gallbladder carcinoma.
Pan, BR; Qin, TJ; Ruan, ZP; Yun, J; Zhang, LX; Zhao, XH, 2008
)
0.56
"GEMOX combined with huachansu (cinobufagin) injection is well tolerated, effective, thus improving the QOL of patients with advanced GBC."( Efficacy and safety of gemcitabine-oxaliplatin combined with huachansu in patients with advanced gallbladder carcinoma.
Pan, BR; Qin, TJ; Ruan, ZP; Yun, J; Zhang, LX; Zhao, XH, 2008
)
0.63
"To discuss and assess the clinical value of treating lung cancer cachexia with thalidomide combined with cinobufagin."( Clinical study on thalidomide combined with cinobufagin to treat lung cancer cachexia.
Bao, Y; Bu, K; Chen, X; Lu, Y; Qin, S; Xie, M, 2018
)
0.96
"Using thalidomide combined with cinobufagin to treat patients with lung cancer cachexia will significantly improve their nutritional status and quality of life."( Clinical study on thalidomide combined with cinobufagin to treat lung cancer cachexia.
Bao, Y; Bu, K; Chen, X; Lu, Y; Qin, S; Xie, M, 2018
)
1.03
"Aim of the study was to observe and analyze the clinical effect of intravenous infusion of zoledronic acid combined with oral medication of cinobufagin in treating metastatic bone tumors."( Clinical effect of intravenous infusion of zoledronic acid combined with oral medication of cinobufagin in the treatment of metastatic bone tumors.
Han, L; Liu, X; Wang, T; Yu, H; Zhang, H; Zhang, J; Zhang, L, 2018
)
0.9
"The main component of cinobufacini injection is dry toad skin, which is used as adjuvant therapy for stage III/IV non-small cell lung cancer patients in long-term combination with vinorelbine and cisplatin."( Efficacy and safety of cinobufacini injection combined with vinorelbine and cisplatin regimen chemotherapy for stage III/IV non-small cell lung cancer: A protocol for systematic review and meta-analysis of randomized controlled trials.
Li, Q; Liang, RL; Peng, XD; Tian, DQ; Wang, WW; Xiao, H; Yong, XJ; Yu, QR; Zhao, LN, 2020
)
0.56
"This study will systematically evaluate the efficacy and safety of cinobufacini combined with vinorelbine and cisplatin in the treatment of stage III/IV non-small cell lung cancer."( Efficacy and safety of cinobufacini injection combined with vinorelbine and cisplatin regimen chemotherapy for stage III/IV non-small cell lung cancer: A protocol for systematic review and meta-analysis of randomized controlled trials.
Li, Q; Liang, RL; Peng, XD; Tian, DQ; Wang, WW; Xiao, H; Yong, XJ; Yu, QR; Zhao, LN, 2020
)
0.56

Bioavailability

ExcerptReferenceRelevance
"Although drug combination has proved to be an efficient strategy for clinic gastric cancer therapy, how to further improve their bioavailability and reduce the side effects are still challenges due to the low solubility and untargeted ability of drugs."( A hybrid membrane coating nanodrug system against gastric cancer
Fan, J; Liu, B; Long, Y; Tong, C; Wang, Z; Yuan, L; Zhao, Y, 2021
)
0.62

Dosage Studied

ExcerptRelevanceReference
" In a single dosing study, the concentration of BF, CB and RB in plasma reached maximum at 1-2 hr after drug administration, and the half-lives (T1/2 of these were 15."( Metabolism and disposition of kyushin, a drug containing senso (ch'an su).
Morishita, S; Shimizu, Y, 1996
)
0.29
" High performance liquid chromatography coupled with the electrospray ionization mass spectrometry techniques of HPLC/ESI-IT-MS/MS and RRLC/ESI-Q-TOF-MS were used for the chemical profiling of samples of dosed plasma, control plasma and ChanSu extract."( Analysis of the bioactive constituents of ChanSu in rat plasma by high performance liquid chromatography with mass spectrometric detection.
Jin, H; Xia, X; Yan, S; Zhang, W, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
steroid lactone
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 3A4Homo sapiens (human)Km24.30001.93005.90608.7000AID1221869; AID1221909
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (19)

Processvia Protein(s)Taxonomy
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (23)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (106)

Assay IDTitleYearJournalArticle
AID1221871Ratio of Vmax/Km in cynomolgus monkey liver microsomes assessed as 5beta-hydroxylcinobufaginn formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221890Drug metabolism in Colony-bred Chinese Bama minipig liver microsomes assessed as 1alpha-hydroxylcinobufagin formation per mg of protein at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221955Drug metabolism in human liver microsomes assessed as 1alpha-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of 10 uM quinidine CYP2D6 inhibitor2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID357628Cytotoxicity against human KB cells after 72 hrs by MTT assay2001Journal of natural products, Sep, Volume: 64, Issue:9
Isolation and structure of five new cancer cell growth inhibitory bufadienolides from the Chinese traditional drug Ch'an Su.
AID759507Cytotoxicity against adriamycin-resistant human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
Discovery of bufadienolides as a novel class of ClC-3 chloride channel activators with antitumor activities.
AID759509Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
Discovery of bufadienolides as a novel class of ClC-3 chloride channel activators with antitumor activities.
AID759510Cytotoxicity against human CNE1 cells assessed as growth inhibition after 48 hrs by MTT assay2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
Discovery of bufadienolides as a novel class of ClC-3 chloride channel activators with antitumor activities.
AID1221933Drug metabolism in cynomolgus monkey liver microsomes assessed as 1alpha-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of NADPH-generating system2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221934Drug metabolism in human liver microsomes assessed as 1alpha-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of NADPH-generating system2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221907Drug metabolism in Colony-bred Chinese Bama minipig liver microsomes assessed as 1alpha-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221938Drug metabolism in cynomolgus monkey liver microsomes assessed as 5beta-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of NADPH-generating system2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221911Ratio of Vmax/Km in cynomolgus monkey liver microsomes assessed as 1alpha-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221954Drug metabolism in human liver microsomes assessed as 5beta-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of 20 uM omeprazole CYP2C19 inhibitor2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID357629Cytotoxicity against human HL60 cells after 72 hrs by MTT assay2001Journal of natural products, Sep, Volume: 64, Issue:9
Isolation and structure of five new cancer cell growth inhibitory bufadienolides from the Chinese traditional drug Ch'an Su.
AID1221920Drug metabolism in Swiss-Hauschka (ICR) mouse liver microsomes assessed as 5beta-hydroxylcinobufaginn formation per mg of protein at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID357630Cytotoxicity against mouse MH60 cells after 72 hrs by MTT assay2001Journal of natural products, Sep, Volume: 64, Issue:9
Isolation and structure of five new cancer cell growth inhibitory bufadienolides from the Chinese traditional drug Ch'an Su.
AID1221912Ratio of Vmax/Km in beagle dog liver microsomes assessed as 1alpha-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221917Drug metabolism in cynomolgus monkey liver microsomes assessed as 5beta-hydroxylcinobufaginn formation per mg of protein at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221910Ratio of Vmax/Km in human liver microsomes assessed as 1alpha-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221888Drug metabolism in cynomolgus monkey liver microsomes assessed as 1alpha-hydroxylcinobufagin formation per mg of protein at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221865Cytotoxicity against human Bel7402 cells assessed as againsthibition of cell growth after 72 hrs2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID773795Cytotoxicity against human A549 cells after 24 hrs by MTT assay2013Journal of natural products, Oct-25, Volume: 76, Issue:10
C23 steroids from the venom of Bufo bufo gargarizans.
AID1221887Drug metabolism in human liver microsomes assessed as 1alpha-hydroxylcinobufagin formation per mg of protein at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID333789Growth inhibition of IL6-dependent mouse MH60 cells after 72 hrs by MTT assay in presence of human recombinant IL62004Journal of natural products, Dec, Volume: 67, Issue:12
Inhibitory effects of bufadienolides on interleukin-6 in MH-60 cells.
AID1221914Ratio of Vmax/Km in Swiss-Hauschka (ICR) mouse liver microsomes assessed as 1alpha-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221944Drug metabolism in human liver microsomes assessed as 5beta-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of 10 uM furafylline CYP1A2 inhibitor2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221896Ratio of Vmax/Km in Colony-bred Chinese Bama minipig liver microsomes assessed as 5beta-hydroxylcinobufaginn formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221940Drug metabolism in Swiss-Hauschka (ICR) mouse liver microsomes assessed as dihydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of NADPH-generating system2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221897Drug metabolism in beagle dog liver microsomes assessed as 1alpha-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of 10 uM furafylline CYP1A2 inhibitor2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221947Drug metabolism in human liver microsomes assessed as 1alpha-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of 50 uM triethylenethiophosphoramide CYP2B6 inhibitor2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221875Drug metabolism in Swiss-Hauschka (ICR) mouse liver microsomes assessed as 1alpha-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of 10 uM furafylline CYP1A2 inhibitor2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221913Ratio of Vmax/Km in Colony-bred Chinese Bama minipig liver microsomes assessed as 1alpha-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID773793Cytotoxicity against KM mouse splenic lymphocytes assessed as cell viability at 5 uM2013Journal of natural products, Oct-25, Volume: 76, Issue:10
C23 steroids from the venom of Bufo bufo gargarizans.
AID1221891Drug metabolism in Swiss-Hauschka (ICR) mouse liver microsomes assessed as 1alpha-hydroxylcinobufagin formation per mg of protein at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221867Drug metabolism in Colony-bred Chinese Bama minipig liver microsomes assessed as 5beta-hydroxylcinobufaginn formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221870Ratio of Vmax/Km in human liver microsomes assessed as 5beta-hydroxylcinobufaginn formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221904Drug metabolism in Swiss-Hauschka (ICR) mouse liver microsomes assessed as 1alpha-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of 1 uM ketoconazole CYP3A4 inhibitor2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221898Drug metabolism in Colony-bred Chinese Bama minipig liver microsomes assessed as 1alpha-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of 10 uM furafylline CYP1A2 inhibitor2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221872Drug metabolism in human liver microsomes assessed as 5beta-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of 10 uM quinidine CYP2D6 inhibitor2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221876Drug metabolism in Colony-bred Chinese Bama minipig liver microsomes assessed as 1alpha-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of 1 uM ketoconazole CYP3A4 inhibitor2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221919Drug metabolism in Colony-bred Chinese Bama minipig liver microsomes assessed as 5beta-hydroxylcinobufaginn formation per mg of protein at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221931Drug metabolism in beagle dog liver microsomes assessed as 1alpha-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of NADPH-generating system2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221889Drug metabolism in beagle dog liver microsomes assessed as 1alpha-hydroxylcinobufagin formation per mg of protein at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221923Drug metabolism in cynomolgus monkey liver microsomes assessed as 5beta-hydroxylcinobufaginn formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221877Drug metabolism in cynomolgus monkey liver microsomes assessed as 1alpha-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of 1 uM ketoconazole CYP3A4 inhibitor2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221892Drug metabolism in human recombinant CYP3A4 expressed in insect cells coexpressing NADPH-P450 reductase assessed as 1alpha-hydroxylcinobufagin formation measured per pmol of enzyme per pmol of protein at 100 uM at 37 degC after 30 mins by UFLC-DAD-ESI-MS 2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221869Drug metabolism in human recombinant CYP3A4 expressed in insect cells coexpressing NADPH-P450 reductase assessed as 5beta-hydroxylcinobufaginn formation measured per pmol of enzyme at 100 uM at 37 degC after 30 mins by UFLC-DAD-ESI-MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221874Drug metabolism in human liver microsomes assessed as 5beta-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of 50 uM clomethiazole CYP2E1 inhibitor2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221873Drug metabolism in human liver microsomes assessed as 1alpha-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of 50 uM clomethiazole CYP2E1 inhibitor2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221939Drug metabolism in human liver microsomes assessed as 5beta-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of NADPH-generating system2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221932Drug metabolism in Colony-bred Chinese Bama minipig liver microsomes assessed as 1alpha-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of NADPH-generating system2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID773796Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay2013Journal of natural products, Oct-25, Volume: 76, Issue:10
C23 steroids from the venom of Bufo bufo gargarizans.
AID1221906Drug metabolism in beagle dog liver microsomes assessed as 1alpha-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID759506Activation of ClC-3 in human CNE2Z cells assessed as increase in chloride current density at +80mV holding potential at 1 uM by whole-cell patch clamp method relative to vehicle-treated control2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
Discovery of bufadienolides as a novel class of ClC-3 chloride channel activators with antitumor activities.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1221918Drug metabolism in beagle dog liver microsomes assessed as 5beta-hydroxylcinobufaginn formation per mg of protein at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221922Drug metabolism in human liver microsomes assessed as 5beta-hydroxylcinobufaginn formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1503774Cytotoxicity against human HL cells assessed as cell viability at 50 uM after 72 hrs by resazurin dye based fluorescence assay relative to control2017Journal of natural products, 10-27, Volume: 80, Issue:10
Identification of Privileged Antichlamydial Natural Products by a Ligand-Based Strategy.
AID155909Inhibitory activity against colchicine resistant parent primary liver carcinoma (PLC) cell line PLC/PRF/52002Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25
QSAR evaluation of the Ch'an Su and related bufadienolides against the colchicine-resistant primary liver carcinoma cell line PLC/PRF/5(1).
AID1221952Drug metabolism in human liver microsomes assessed as 5beta-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of 10 uM sulfaphenazole CYP2C9 inhibitor2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID759508Cytotoxicity against human CNE2Z cells assessed as growth inhibition after 48 hrs by MTT assay2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
Discovery of bufadienolides as a novel class of ClC-3 chloride channel activators with antitumor activities.
AID1221950Drug metabolism in human liver microsomes assessed as 5beta-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of 2 uM montelukast CYP2C8 inhibitor2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221900Drug metabolism in Swiss-Hauschka (ICR) mouse liver microsomes assessed as 1alpha-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of 10 uM sulfaphenazole CYP2C9 inhibitor2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID310229Cytotoxicity against human BGC823 cells2007Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22
Microbial transformation of three bufadienolides by Nocardia sp. and some insight for the cytotoxic structure-activity relationship (SAR).
AID1221948Drug metabolism in human liver microsomes assessed as 5beta-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of 50 uM triethylenethiophosphoramide CYP2B6 inhibitor2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221945Drug metabolism in human liver microsomes assessed as 1alpha-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of 2.5 uM 8-methoxypsoralen CYP2A6 inhibitor2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID127352Binding affinity against human monoclonal antibody (mAb)-7F22002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID1221943Drug metabolism in human liver microsomes assessed as 1alpha-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of 10 uM furafylline CYP1A2 inhibitor2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221864Ratio of Vmax/Km in human recombinant CYP3A4 expressed in insect cells coexpressing NADPH-P450 reductase assessed as 5beta-hydroxylcinobufaginn formation measured per pmol of enzyme at 100 uM at 37 degC after 30 mins by UFLC-DAD-ESI-MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221921Drug metabolism in human recombinant CYP3A4 expressed in insect cells coexpressing NADPH-P450 reductase assessed as 5beta-hydroxylcinobufaginn formation measured per pmol of enzyme per pmol of protein at 100 uM at 37 degC after 30 mins by UFLC-DAD-ESI-MS 2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID343717Cytotoxicity against human Bel7402 cells by MTT assay2008Journal of natural products, Jul, Volume: 71, Issue:7
Microbial transformation of cinobufagin by Syncephalastrum racemosum.
AID1221895Ratio of Vmax/Km in beagle dog liver microsomes assessed as 5beta-hydroxylcinobufaginn formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221953Drug metabolism in human liver microsomes assessed as 1alpha-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of 20 uM omeprazole CYP2C19 inhibitor2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221951Drug metabolism in human liver microsomes assessed as 1alpha-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of 10 uM sulfaphenazole CYP2C9 inhibitor2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221935Drug metabolism in Swiss-Hauschka (ICR) mouse liver microsomes assessed as 5beta-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of NADPH-generating system2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221930Drug metabolism in Swiss-Hauschka (ICR) mouse liver microsomes assessed as 1alpha-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of NADPH-generating system2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID155910Inhibitory activity against the primary liver carcinoma (PLC) cell line PLC/PRF/52002Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25
QSAR evaluation of the Ch'an Su and related bufadienolides against the colchicine-resistant primary liver carcinoma cell line PLC/PRF/5(1).
AID127349Binding affinity against human monoclonal antibody (mAb)-11E62002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID1221903Drug metabolism in cynomolgus monkey liver microsomes assessed as 1alpha-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of 10 uM sulfaphenazole CYP2C9 inhibitor2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221937Drug metabolism in Colony-bred Chinese Bama minipig liver microsomes assessed as 5beta-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of NADPH-generating system2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221894Drug metabolism in cynomolgus monkey liver microsomes assessed as 1alpha-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221936Drug metabolism in beagle dog liver microsomes assessed as 5beta-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of NADPH-generating system2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID310227Cytotoxicity against human HepG2 cells2007Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22
Microbial transformation of three bufadienolides by Nocardia sp. and some insight for the cytotoxic structure-activity relationship (SAR).
AID1221946Drug metabolism in human liver microsomes assessed as 5beta-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of 2.5 uM 8-methoxypsoralen CYP2A6 inhibitor2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221908Drug metabolism in Swiss-Hauschka (ICR) mouse liver microsomes assessed as 1alpha-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221941Drug metabolism in human liver microsomes assessed as 1alpha-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of 1 uM ketoconazole CYP3A4 inhibitor2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1221863Ratio of Vmax/Km in Swiss-Hauschka (ICR) mouse liver microsomes assessed as 5beta-hydroxylcinobufaginn formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221866Drug metabolism in beagle dog liver microsomes assessed as 5beta-hydroxylcinobufaginn formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221905Drug metabolism in beagle dog liver microsomes assessed as 1alpha-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of 1 uM ketoconazole CYP3A4 inhibitor2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID759465Cytotoxicity against mouse S180 cells expressing mutated alpha-1 Na+/K+-ATPase assessed as growth inhibition after 48 hrs by MTT assay2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
Discovery of bufadienolides as a novel class of ClC-3 chloride channel activators with antitumor activities.
AID1221899Drug metabolism in cynomolgus monkey liver microsomes assessed as 1alpha-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of 10 uM furafylline CYP1A2 inhibitor2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID759464Cytotoxicity against mouse H22 cells expressing mutated alpha-1 Na+/K+-ATPase assessed as growth inhibition after 48 hrs by MTT assay2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
Discovery of bufadienolides as a novel class of ClC-3 chloride channel activators with antitumor activities.
AID310228Cytotoxicity against human HeLa cells2007Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22
Microbial transformation of three bufadienolides by Nocardia sp. and some insight for the cytotoxic structure-activity relationship (SAR).
AID127350Binding affinity against human monoclonal antibody (mAb)-1B32002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID127351Binding affinity against human monoclonal antibody (mAb)-5C22002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID1221949Drug metabolism in human liver microsomes assessed as 1alpha-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of 2 uM montelukast CYP2C8 inhibitor2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221909Drug metabolism in human recombinant CYP3A4 expressed in insect cells coexpressing NADPH-P450 reductase assessed as 1alpha-hydroxylcinobufagin formation measured per pmol of enzyme at 100 uM at 37 degC after 30 mins by UFLC-DAD-ESI-MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID333788Growth inhibition of IL-6-independent mouse MH60 cells after 72 hrs by MTT assay2004Journal of natural products, Dec, Volume: 67, Issue:12
Inhibitory effects of bufadienolides on interleukin-6 in MH-60 cells.
AID1221868Drug metabolism in Swiss-Hauschka (ICR) mouse liver microsomes assessed as 5beta-hydroxylcinobufaginn formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221901Drug metabolism in beagle dog liver microsomes assessed as 1alpha-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of 10 uM sulfaphenazole CYP2C9 inhibitor2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221902Drug metabolism in Colony-bred Chinese Bama minipig liver microsomes assessed as 1alpha-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of 10 uM sulfaphenazole CYP2C9 inhibitor2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221915Ratio of Vmax/Km in human recombinant CYP3A4 expressed in insect cells coexpressing NADPH-P450 reductase assessed as 1alpha-hydroxylcinobufagin formation measured per pmol of enzyme at 100 uM at 37 degC after 30 mins by UFLC-DAD-ESI-MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221942Drug metabolism in human liver microsomes assessed as 5beta-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of 1 uM ketoconazole CYP3A4 inhibitor2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221893Drug metabolism in human liver microsomes assessed as 1alpha-hydroxylcinobufagin formation at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221916Drug metabolism in human liver microsomes assessed as 5beta-hydroxylcinobufaginn formation per mg of protein at 100 uM at 37 degC after 30 mins by UFLC-ESI-MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (130)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (7.69)18.7374
1990's11 (8.46)18.2507
2000's23 (17.69)29.6817
2010's59 (45.38)24.3611
2020's27 (20.77)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.28 (24.57)
Research Supply Index4.91 (2.92)
Research Growth Index5.00 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (1.50%)5.53%
Reviews1 (0.75%)6.00%
Case Studies3 (2.26%)4.05%
Observational0 (0.00%)0.25%
Other127 (95.49%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]